

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE

Las Vegas, NV

Las Vegas Flamingo Hotel

3555 South Las Vegas Blvd.

FRI., MARCH 31 & SAT., APRIL 1

1:00pm – 6:00pm 8:00am – 12:00pm

A special guest room rate is available for participants—
Go to: book.passkey.com/go/SFCLD3 for more details.
These rates are only available until March 9th.



For More Information
and to Register:

<http://bit.ly/hepandCLD23>

Pre-Registration is encouraged.

For seminar specific information, contact cme@scliver.com

This face-to-face seminar focuses on key challenges in the prevention, treatment and patient management approaches associated with viral hepatitis, advancing cirrhosis, liver cancer, fatty liver disease and other hepatic conditions. The updated content is drawn from latest medical guidelines and clinical trial results.

A hybrid format combines live lectures with web-based pre- and post-program assignments. Local faculty experts will deliver state-of-the-art material utilizing a curriculum that features lectures, case analysis, current clinical trial outcomes and progress reports on promising diagnostic approaches and emerging therapies.

The seminar is also available as a web-based, self paced Enduring Material.

Topics to be covered include:

- ▶ Viral Hepatitis: The origins and pathways of HBV, HCV and the growing incidence of Delta Hepatitis
- ▶ Hepatitis vaccines, prevention models and avoiding reactivation of the virus
- ▶ The elimination of Hepatitis B
- ▶ Ascites, Hepatorenal Syndrome and Hepatic Encephalopathy
- ▶ New data on the impact of SARS-CoV-2 on the liver
- ▶ End-stage liver disease, cirrhosis, tumor reduction and transplant options
- ▶ The growing influence of alcohol on liver disease
- ▶ Hepatocellular Carcinoma – management approaches and new immunotherapies
- ▶ Identifying and treating Fatty Liver Disease and NASH
- ▶ PBS and PSC – the latest outcomes from EASL and AASLD
- ▶ Treating and curing liver disease in special populations

Those who complete this activity will better identify how to screen, diagnose and treat their patients with Viral Hepatitis, Cirrhosis, Liver Cancer, Fatty Liver Disease and more.



**Michael Volk,
MD, MSc**
Loma Linda
University



**Sammy Saab,
MD, MPH**
UCLA Geffen School
of Medicine



**Corrie Berk,
DNP, MBA**
Loma Linda Transplant
Institute

JOINT PROVIDER STATEMENT

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership

of the University of Louisville and SC Liver Research Consortia. The University of Louisville is accredited by the ACCME to provide continuing medical education for physicians.



DESIGNATION STATEMENTS

Physicians - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1317. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

This course is supported in part by an educational grant from industry, in accordance with ACCME accreditation Standards of Commercial Support.

**Physicians and
Pharmacists**
\$195

SEMINAR TUITION

**PA's, NP's and
Nurses**
\$95

**Residents and
Fellows**
\$75